Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | STAT3 | P40763 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 7/20 | 0.41 |
| ▸ | LMNA | P02545 | 7/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | HPGD | P15428 | 6/20 | 0.41 |
| ▸ | POLB | P06746 | 6/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 4/20 | 0.41 |
| ▸ | RECQL | P46063 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.40 |
| ▸ | HTT | P42858 | 4/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | BLM | P54132 | 2/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21317741 | 0.85 | AOC1 (0.45) | MAPK1STAT3MAPTLMNASMN1; SMN2 | |
| SCHEMBL18988717 | 0.84 | STAT3 (0.43) | MAPK1STAT3MAPTLMNASMN1; SMN2 | |
| SCHEMBL15173341 | 0.82 | MAPK1 (0.46) | MAPK1STAT3MAPTLMNASMN1; SMN2 | |
| SCHEMBL10409284 | 0.80 | CNR2 (0.49) | MAPK1LMNAPOLBCYP1A2CYP2D6 | |
| SCHEMBL1993769 | 0.80 | MAPK1 (0.48) | MAPK1MAPTLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL13793862 | 0.79 | STAT3 (0.43) | MAPK1STAT3MAPTLMNASMN1; SMN2 | |
| SCHEMBL10409254 | 0.79 | PTGER4 (0.44) | MAPK1MAPTLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL18398209 | 0.79 | MAPK1 (0.45) | MAPK1STAT3MAPTLMNASMN1; SMN2 | |
| SCHEMBL10408673 | 0.79 | CNR2 (0.48) | MAPK1LMNAPOLBCYP1A2CYP2D6 | |
| SCHEMBL10408187 | 0.79 | CNR2 (0.48) | MAPK1LMNAPOLBCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278455-B2 | 5- or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-10-02 | — | — | US | disclosed |
| US-8278455-B2 | 5- or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-10-02 | — | — | US | disclosed |
| US-20090062278-A1 | 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | JANSSEN SCIENCES IRELAND UC (IE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062278-A1 | 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | JANSSEN SCIENCES IRELAND UC (IE) | 2009-03-05 | — | — | US | disclosed |
| US-20070093502-A1 | 5- Or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | BONFANTI JEAN-FRANCOIS | 2007-04-26 | — | — | US | disclosed |
| US-20070093502-A1 | 5- Or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | BONFANTI JEAN-FRANCOIS | 2007-04-26 | — | — | US | disclosed |
| WO-2005058874-A1 | 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2005-06-30 | — | — | WO | disclosed |
| US-4925984-A | REACTION WITH BROMINE IN SOLUTION | ETHYL CORPORATION (US) | 1990-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093502-A1 | 5- Or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SUB1, HYOU1 | MAPK1 2083/4885STAT3 1084/4885MAPT 4884/4885 |
| US-20090062278-A1 | 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYC1, SUB1 | MAPK1 1136/4885STAT3 1376/4885MAPT 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.